Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Routine treatment + Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day
Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine
Sponsors
Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia, clinical classification is ordinary or heavy; 2. TCM syndrome differentiation is wind-heat syndrome; 3. Aged between 18-75 years old, regardless of gender; 4. Voluntarily sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development; 2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis; 3. Severe pneumonia requires mechanical ventilation; 4. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .; 5. Pregnant or lactating women; 6. Patients who participated in other clinical trials within the last 3 months; 7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug; 8. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clearance rate and time of main symptoms (fever, fatigue, cough); | — |
Secondary
| Measure | Time frame |
|---|---|
| Chest imaging;Refers to oxygen saturation;Respiratory rate;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death;Cure rate;TCM symptoms and tongue and pulse assessment before and after treatment; | — |
Countries
China
Contacts
Public ContactLiu Hua/Wang Qian
Shanghai University of Traditional Chinese Medicine
Outcome results
None listed